DS
DSGN.US Design Therapeutics Inc
- Market cap
- USD 670M
- P/E
- -
- P/B
- 3.35x
- ROE
- -38.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DSGN.US undervalued?
Graham numberThe Graham number of Design Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Design Therapeutics Inc fundamental analysis
No fundamental analysis for Design Therapeutics Inc yet.
Design Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autos…
Full company profileDesign Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Design Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 834K | 226.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -820.00 | -5.00K | -129K | -466K | -537K | -596K | -622K | - |
| Operating Income | -1.91M | -8.56M | -35.8M | -67.6M | -78.2M | -62.4M | -79.5M | -85.5M |
| EBITDA | -1.91M | -8.28M | -35.4M | -67.2M | -66.3M | -49.0M | -69.2M | -82.1M |
| Net Income | -2.05M | -8.28M | -35.5M | -58.6M | -66.9M | -49.6M | -69.8M | -77.5M |
| EPS | -0.08 | -0.30 | -0.77 | -1.05 | -1.19 | -0.88 | -1.22 | -1.23 |
| Balance Sheet | ||||||||
| Total Assets | 90.0K | 36.5M | 391M | 341M | 290M | 252M | 226M | 217M |
| Total Liabilities | 3.73M | 47.8M | 8.43M | 13.8M | 12.0M | 10.00M | 13.7M | 14.6M |
| Shareholders' Equity | -3.64M | -11.3M | 382M | 327M | 278M | 242M | 213M | 202M |
| Cash & Short-term Investments | 77.0K | 36.1M | 384M | 330M | 282M | 245M | 220M | 209M |
| Total Debt | 695K | - | 3.63M | 3.69M | 3.05M | 2.33M | 1.54M | 2.51M |
| Cash Flow | ||||||||
| Operating Cash Flow | -139K | -8.67M | -29.4M | -51.3M | -58.6M | -43.1M | -54.4M | -63.1M |
| Capital Expenditure | 76.0K | 76.0K | 1.54M | 918K | 256K | 340K | 193K | 48.0K |
| Free Cash Flow | -139K | -8.75M | -30.9M | -52.2M | -58.8M | -43.4M | -54.6M | -63.2M |
| Ratios | ||||||||
| ROE | - | - | -9.3% | -17.9% | -24.1% | -20.5% | -32.8% | -38.3% |
| ROA | -2,274.4% | -22.7% | -9.1% | -17.2% | -23.1% | -19.7% | -30.9% | -35.7% |
| Net Profit Margin | -245.4% | -3,663,716.8% | - | - | - | - | - | - |
| Debt to Equity | - | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Design Therapeutics Inc dividends
Design Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Design Therapeutics Inc
- Insiders 31.24%
- Institutions 68.77%
- Public & others 0.00%
- Shares outstanding 64.0M
- Free float 37.6M
Top funds holding DSGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.19M | 1.86% | +2.49% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.00M | 1.57% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 798K | 1.25% | 0.00% | Oct 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 561K | 0.88% | +21.93% | Sep 2026 |
| Fidelity Select Biotechnology | 535K | 0.84% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 337K | 0.53% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 292K | 0.46% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 269K | 0.42% | -0.19% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 254K | 0.40% | +0.27% | Oct 2026 |
| Driehaus Micro Cap Growth USD | 228K | 0.36% | +23.54% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 206K | 0.32% | +0.23% | Oct 2026 |
| AZ Fd 1 - AZ Eq - Amer Opps A-EUR Acc | 204K | 0.32% | +4.59% | Sep 2026 |
| Fidelity Extended Market Index | 180K | 0.28% | +12.69% | Sep 2026 |
| Vanguard Russell 2000 ETF | 179K | 0.28% | +1.24% | Sep 2026 |
| Dimensional US Small Cap ETF | 156K | 0.24% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap I | 134K | 0.21% | -1.03% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 129K | 0.20% | -0.54% | Oct 2026 |
| RBC Private U.S. Small-Cap Eqty Pool F | 128K | 0.20% | +0.53% | Sep 2026 |
| North Square Dynamic Small Cap I | 127K | 0.20% | -12.39% | Jun 2026 |
| DFA US Micro Cap I | 116K | 0.18% | -1.28% | Sep 2026 |
Top institutions holding DSGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 6.53M | 10.19% | 0.00% | Jun 2026 |
| Logos Global Management LP | 3.00M | 4.68% | +53.85% | Jun 2026 |
| Baker Bros Advisors LP | 2.68M | 4.18% | +3.58% | Jun 2026 |
| Driehaus Capital Management LLC | 2.66M | 4.16% | +52.50% | Jun 2026 |
| BlackRock Inc | 2.66M | 4.15% | +24.66% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.37M | 3.70% | -13.09% | Jun 2026 |
| Trails Edge Capital Partners, LP | 2.00M | 3.13% | +134.89% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 1.81M | 2.83% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 1.61M | 2.52% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.57M | 2.45% | +16.38% | Jun 2026 |
| Caption Management, LLC | 1.12M | 1.75% | +1,189.50% | Jun 2026 |
| Almitas Capital LLC | 1.03M | 1.60% | -32.90% | Jun 2026 |
| Geode Capital Management, LLC | 958K | 1.50% | +38.40% | Jun 2026 |
| Sofinnova Ventures | 865K | 1.35% | 0.00% | Jun 2026 |
| FMR Inc | 776K | 1.21% | -2.75% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 765K | 1.20% | +16.58% | Jun 2026 |
| State Street Corp | 736K | 1.15% | +11.62% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 728K | 1.14% | +4.72% | Sep 2026 |
| Woodline Partners LP | 700K | 1.09% | -27.16% | Jun 2026 |
| The Goldman Sachs Group Inc | 657K | 1.03% | +30.09% | Jun 2026 |
Design Therapeutics Inc company profile
- Company name
- Design Therapeutics Inc
- Ticker
- DSGN.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Fiscal year end
- December
- Address
- 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011
- Phone
- 858 293 4900
- Website
- designtx.com
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Design Therapeutics Inc management
10- Mr. Pratik Shah Ph.D.Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson · born 1970
- Dr. Sean Jeffries Ph.D.Chief Operating Officer · born 1980
- Dr. Chris M. Storgard M.D.Chief Medical Officer · born 1966
- Dr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific Advisor
- Ms. Julie D. Burgess CPAChief Accounting Officer
- Mr. Doane Chilcoat Ph.D.Chief Technology Officer
- Mr. Mustapha ParekhGeneral Counsel
- Dr. Tadimeti S. Rao Ph.D.Chief Scientific Officer
- Mr. Jim KerrChief of Manufacturing & Product Development
- Dr. Chengzhi Zhang Ph.D.Chief Chemist